BioStem Technologies, Inc. — Form 8-K
Filed September 30, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 28/100
What the filing says
BioStem Technologies (Sept 29, 2026) conducted a private placement of up to $3,000,008 in common stock and warrants. Investors receive shares at $4.08/share plus Series A warrants (5-yr, $3.83 exercise) and Series B warrants (24-month, $3.83 exercise) at 100% of share purchase amount. Company must register resale within 30-45 days (75 days if 'full review'), with 1% monthly liquidated damages if registration delayed >10 days/month, capped at 6% total. Counterparties are unnamed accredited investors; Placement Agent is H.C. Wainwright & Co. No specific dollar amounts per investor disclosed in template.
Why this rating
Routine equity financing ~6% of $48.8M asset base. Standard warrant dilution and registration mechanics. No material acquisition, license, or go-concern event. Typical for micro-cap biotech.
See more from September 30, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.